Mrs. Asavari Anirudha Joshi

Profile

Date of Birth: 18-04-1979

Qualification: M.Sc. Microbiology

Designation: Scientist

Contacts

e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Phone: 020-24366920 (ext: 520)

Research experience:

Around twelve years of research experience includes both academic and industrial exposure. Development of explants and primary cell cultures from knee cartilage to evaluate chondro-protective activity of various herbal extracts has been enriching. Involvement in drug discovery and development for cancer at Piramal Life Sciences Ltd has been extremely educational and inspiring.

  • Jan 2015-present CINHD, Pune

    • Working as a Scientist
    • Carrying out research in the field of oncology and degenerative diseases
    • Monitoring activities in the animal tissue culture laboratory
  • Nov2007 – Nov2014 (7 years) Piramal Life Sciences, Mumbai.

    • Worked in the Oncology Therapeutic area as Research Scientist
    • Worked on different targets (signaling pathways) relevant to cancer (major contribution in the discovery of IND molecule, received award for the same)
    • Worked to further decipher mechanism of action for the molecules already in the clinical trials
    • Handled human tumor samples, developed the primary cell cultures and evaluated anticancer potential of standard and in house drug candidates
  • March 2007- May2007 (3 months) Himedia Laboratories, Mumbai

    • Worked as Scientist
    • Involved in Production and Quality assurance for different tissue culture related products
  • July 2002-Nov2006 (4 year) Interactive Research School for health’s affair, Pune

    • Worked as a Research Associate for CSIR funded project
    • Handled human cartilage samples, developed primary chondrocytes cultures and evaluated effect of different herbal extracts on these primary cultures.

Areas of interest:

  • Oncology and Degenerative Diseases

Honors/awards

Received Award for significant contribution in “Drug Development of New Chemical Entity for anti-cancer activity” in 2011 (Piramal Life Sciences Ltd.)

Publications: 07

Research Programmes

Deciphering mechanism of action of various anti-cancer drugs alone or in combination at cell signaling level has been the key focus. Work is being carried out using various cell lines and patient derived clinical samples with emphasis on breast cancer and flax lignan.

Publications

Publications

  1. Aniket V Mali, Asavari A Joshi, Mahabaleshwar V Hegde, and Shivajirao S Kadam. Enterolactone suppresses proliferation, migration and metastasis of MDA-MB231 breast cancer cells through inhibition of uPA induced plasmin activation and MMPs-mediated ECM remodelling. APJCP. 2017; 18(4):905-915.
  2. Archana Jalota-Badhwar, Dimple Bhatia, Srinivas Reddy Boreddy, Asavari Joshi, Magesh Venkatraman, Nikesh Desai, Sarika Chaudhari, Julie Bose, Lakshmi Sireesha Kolla, Vijaykumar Deore, Nilambari Yewalkar, Sanjay Kumar, Rajiv Sharma, Anagha Damre, Avinash More, Prakash Gill, Somesh Sharma, and Veena Agarwal. P7170: a potent and novel molecule with unique profile of mTORC1/mTORC2, and Activin Receptor-Like Kinase 1 (ALK1) inhibition leading to anti-tumor and anti-angiogenic activity. Mol Cancer Ther. 2015; 14(5):1095-106.
  3. Venkatasubbaiah A Venkatesha, Asavari A Joshi, Magesh Venkataraman, Vinay Sonawane, Prashant K Pandey, Julie Bose, Sarika A Choudhari, Dimple Bhatia, Ankita Srivastava, Vaibhavi Lad, Parkash Gill, Ramachandra Sangana, Tausif Ahmed, Anagha Damre, Vijaykumar Deore, Bichismita Sahu, Sanjay Kumar, Somesh Sharma and Veena Agarwal. P7170, a novel inhibitor of mTORC1/mTORC2 and Activin Receptor-Like Kinase 1 (ALK1) inhibits the growth of Non Small Cell Lung Cancer. Mol Cancer. 2014; 13:259.
  4. Pallavi Godse, Pramod Kumar, Nilambari Yewalkar, Vijaykumar Deore, Manoj Lohar, Ramswaroop Mundada, Amol Padgaonkar, Sonal Manohar, Asavari Joshi, Dimple Bhatia, Nikesh Desai, Anagha Damre, Mandar Bhonde, Kalpana Joshi, Rajiv Sharma, and Sanjay Kumar. Discovery of P3971 an orally efficacious novel anticancer agent targeting HIF-1α and STAT3 pathways. Anticancer Agents Med Chem. 2013; 13(9):1460-6.
  5. Venil N Sumantran, Asavari Kulkarni, Rucha Chandwaskar, Abhay Harsulkar, Bhushan Patwardhan,Arvind Chopra, and Ulhas V Wagh. Chondroprotective Potential of Fruit Extracts of Phyllanthus emblica in Osteoarthritis. Evid Based Complement Alternat Med. 2008; 5(3):329-35.
  6. Venil N Sumantran, Rucha Chandwaskar, Asavari Kulkarni Joshi, Sanjay Boddul, Bhushan Patwardhan, Arvind Chopra, and Ulhas V Wagh. The relationship between chondroprotective and antiinflammatory effects of Withania somnifera root and glucosamine sulphate on human osteoarthritic cartilage in vitro. Phytother Res. 2008; 22(10):1342-8.
  7. Venil N Sumantran, Asavari A Kulkarni, Abhay Harsulkar, Asmita Wele, Soumya J Koppikar, Rucha Chandwaskar,Vishakha Gaire, Madhuri Dalvi, and Ulhas V Wagh. Hyaluronidase and collagenase inhibitory activities of the herbal formulation Triphala guggulu. J Biosci. 2007; 32(4):755-61.
  8. Venil N Sumantran, Asavari Kulkarni, Sanjay Boddul, Trushna Chinchwade, Soumya J Koppikar, Abhay Harsulkar, Bhushan Patwardhan, Arvind Chopra, and Ulhas V Wagh. Chondro protective potential of root extracts of Withania somnifera in osteoarthritis. J Biosci. 2007; 32(2):299-307.

Book Chapter

  1. Asavari A. Joshi, Mahabaleshwar V. Hegde and Sharad P. Adekar. Omega-3 Fatty Acids in Cancer: Insight into the Mechanism of Actions in Preclinical Cancer Models. In: Anand A. Zanwar, Sharad P. Adekar and Mahabaleshwar V. Hegde, ed(s). Omega-3 Fatty Acids – Keys to Nutritional Health. Switzerland: Springer International Publishing; 2016:157-172.